FDA Panel Gives Thumbs Down to Novel Strategy for Switching Breast Cancer Therapy

MedPage Today) — A novel strategy for switching breast cancer therapy intrigued members of an FDA advisory committee but failed to sway the panel to recommend approval of the strategy.
By a 6-3 vote, the Oncologic Drugs Advisory Committee (ODAC…
Read More

About The Author

Jonathan Jeriah

See author's posts